Abstract
A multi-centre, randomised, double-blinded, active-controlled, parallel-group clinical trial was carried out to assess the immunogenicity and safety of NBP608—a newly developed live-attenuated zoster vaccine in Korea—relative to Zostavax® in healthy adults aged 50 years or older. Immune responses to the vaccine were evaluated by glycoprotein enzyme-linked immunosorbent assay (gpELISA)and enzyme-linked immunosorbent spot (ELISPOT)assays using the interferon (IFN)-γ and interleukin (IL)-2 FluoroSpot kit 6 weeks after vaccination. Safety was monitored for 26 weeks based on subjects’ diaries, spontaneous reports from subjects, and history taking by the investigators. A total of 845 subjects participated in the screening, and 823 received the vaccination (413 in the NBP608 group and 411 in the comparator group). The gpELISA-determined geometric mean fold rise from baseline to post NBP608 vaccination was 2.75 [95% confidence interval, CI (2.57, 2.94)]. The gpELISA-determined adjusted geometric mean titers (GMTs)of NBP608 and the comparator were 1346.37 [95% CI (1273.99, 1422.87)]and 1674.94 [95% CI (1585.35, 1769.58)], respectively. The adjusted GMT ratio of NBP608 to the comparator was 0.80 [95% CI (0.75, 0.87)]. There was no statistically significant difference between two groups in terms of the geometric mean spot numbers determined by IFN-γ and IL-2 ELISPOT assays at 6 weeks post vaccination (P = 0.7232, 0.3844). The incidence of adverse events (AEs)within 6 weeks post vaccination was 49.82% overall (410/823, 941 cases), 50.73% (209/412, 474 cases)in the NBP608 group, and 48.91% (201/411, 467 cases)in the comparator group. The difference in AE rate between the two groups was not statistically significant (P = 0.6010). Most AEs were mild, with a rate of 83.12% in the NBP608 group and 75.37% in the comparator group. Thus, NBP608 is non-inferior to Zostavax® in terms of inducing the immune response and can be safely administered to adults aged 50 years or older. ClinicalTrials.gov Identifier: NCT03120364.
| Original language | English |
|---|---|
| Journal | Vaccine |
| DOIs | |
| Publication status | Published - 2019 Jan 1 |
Fingerprint
Keywords
- Attenuated vaccine
- Clinical trial
- Herpes zoster vaccine
- Immunogenicity
- Prevention of herpes zoster
- Safety
ASJC Scopus subject areas
- Molecular Medicine
- Immunology and Microbiology(all)
- veterinary(all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases
Cite this
Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608)compared to Zostavax® in healthy adults aged 50 years and older. / Choi, Wonseok; Choi, Jung Hyun; Jung, Dong Sik; Choi, Hee Jung; Kim, Yeon Sook; Lee, Jacob; Jang, Hee Chang; Shin, Eui Cheol; Park, Jun Sik; Kim, Hun; Cheong, Hee-Jin.
In: Vaccine, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608)compared to Zostavax® in healthy adults aged 50 years and older
AU - Choi, Wonseok
AU - Choi, Jung Hyun
AU - Jung, Dong Sik
AU - Choi, Hee Jung
AU - Kim, Yeon Sook
AU - Lee, Jacob
AU - Jang, Hee Chang
AU - Shin, Eui Cheol
AU - Park, Jun Sik
AU - Kim, Hun
AU - Cheong, Hee-Jin
PY - 2019/1/1
Y1 - 2019/1/1
N2 - A multi-centre, randomised, double-blinded, active-controlled, parallel-group clinical trial was carried out to assess the immunogenicity and safety of NBP608—a newly developed live-attenuated zoster vaccine in Korea—relative to Zostavax® in healthy adults aged 50 years or older. Immune responses to the vaccine were evaluated by glycoprotein enzyme-linked immunosorbent assay (gpELISA)and enzyme-linked immunosorbent spot (ELISPOT)assays using the interferon (IFN)-γ and interleukin (IL)-2 FluoroSpot kit 6 weeks after vaccination. Safety was monitored for 26 weeks based on subjects’ diaries, spontaneous reports from subjects, and history taking by the investigators. A total of 845 subjects participated in the screening, and 823 received the vaccination (413 in the NBP608 group and 411 in the comparator group). The gpELISA-determined geometric mean fold rise from baseline to post NBP608 vaccination was 2.75 [95% confidence interval, CI (2.57, 2.94)]. The gpELISA-determined adjusted geometric mean titers (GMTs)of NBP608 and the comparator were 1346.37 [95% CI (1273.99, 1422.87)]and 1674.94 [95% CI (1585.35, 1769.58)], respectively. The adjusted GMT ratio of NBP608 to the comparator was 0.80 [95% CI (0.75, 0.87)]. There was no statistically significant difference between two groups in terms of the geometric mean spot numbers determined by IFN-γ and IL-2 ELISPOT assays at 6 weeks post vaccination (P = 0.7232, 0.3844). The incidence of adverse events (AEs)within 6 weeks post vaccination was 49.82% overall (410/823, 941 cases), 50.73% (209/412, 474 cases)in the NBP608 group, and 48.91% (201/411, 467 cases)in the comparator group. The difference in AE rate between the two groups was not statistically significant (P = 0.6010). Most AEs were mild, with a rate of 83.12% in the NBP608 group and 75.37% in the comparator group. Thus, NBP608 is non-inferior to Zostavax® in terms of inducing the immune response and can be safely administered to adults aged 50 years or older. ClinicalTrials.gov Identifier: NCT03120364.
AB - A multi-centre, randomised, double-blinded, active-controlled, parallel-group clinical trial was carried out to assess the immunogenicity and safety of NBP608—a newly developed live-attenuated zoster vaccine in Korea—relative to Zostavax® in healthy adults aged 50 years or older. Immune responses to the vaccine were evaluated by glycoprotein enzyme-linked immunosorbent assay (gpELISA)and enzyme-linked immunosorbent spot (ELISPOT)assays using the interferon (IFN)-γ and interleukin (IL)-2 FluoroSpot kit 6 weeks after vaccination. Safety was monitored for 26 weeks based on subjects’ diaries, spontaneous reports from subjects, and history taking by the investigators. A total of 845 subjects participated in the screening, and 823 received the vaccination (413 in the NBP608 group and 411 in the comparator group). The gpELISA-determined geometric mean fold rise from baseline to post NBP608 vaccination was 2.75 [95% confidence interval, CI (2.57, 2.94)]. The gpELISA-determined adjusted geometric mean titers (GMTs)of NBP608 and the comparator were 1346.37 [95% CI (1273.99, 1422.87)]and 1674.94 [95% CI (1585.35, 1769.58)], respectively. The adjusted GMT ratio of NBP608 to the comparator was 0.80 [95% CI (0.75, 0.87)]. There was no statistically significant difference between two groups in terms of the geometric mean spot numbers determined by IFN-γ and IL-2 ELISPOT assays at 6 weeks post vaccination (P = 0.7232, 0.3844). The incidence of adverse events (AEs)within 6 weeks post vaccination was 49.82% overall (410/823, 941 cases), 50.73% (209/412, 474 cases)in the NBP608 group, and 48.91% (201/411, 467 cases)in the comparator group. The difference in AE rate between the two groups was not statistically significant (P = 0.6010). Most AEs were mild, with a rate of 83.12% in the NBP608 group and 75.37% in the comparator group. Thus, NBP608 is non-inferior to Zostavax® in terms of inducing the immune response and can be safely administered to adults aged 50 years or older. ClinicalTrials.gov Identifier: NCT03120364.
KW - Attenuated vaccine
KW - Clinical trial
KW - Herpes zoster vaccine
KW - Immunogenicity
KW - Prevention of herpes zoster
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=85065763539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065763539&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2019.04.046
DO - 10.1016/j.vaccine.2019.04.046
M3 - Article
JO - Vaccine
JF - Vaccine
SN - 0264-410X
ER -